In our case, the presumptive diagnosis was recurrent hyphema possibly related to coagulation abnormalities inherent in the patient’s chronic lymphocytic leukemia, with the patient’s treatment with BTK inhibitor ibrutinib also inhibiting BTK-dependent platelet aggregation. This evidence concerns the gene BTK and Hyphema.